Tumor Biology

, Volume 36, Issue 4, pp 2377–2381 | Cite as

Inhibition of prostatic cancer growth by ginsenoside Rh2

  • Qingchuan Zhang
  • Bin Hong
  • Songhua Wu
  • Tianli Niu
Research Article


Ginsenoside Rh2 (GRh2) has been reported to have therapeutic effects on some types of cancer, but its effect on prostatic cancer has not been extensively evaluated. Here, we show that GRh2 can substantially inhibit the growth of prostatic cancer in vivo and in vitro. Moreover, the inhibition of the tumor growth appeared to result from a combined inhibitory effect on tumor cell proliferation and tumor cell invasiveness. Further analyses suggest that GRh2 seemed to activate transforming growth factor β (TGFβ) receptor signaling in prostatic cancer cells, which subsequently inhibits cell proliferation and invasion through regulating cell-cycle controllers and (MMPs), respectively. Taken together, our data reveal an essential anti-prostatic cancer effect of GRh2 and demonstrate that this effect is through augment of TGFβ receptor signaling in the prostatic cancer cells. GRh2 thus appears to be a promising therapy for prostatic cancer.


Prostatic cancer Ginsenoside Rh2 Transforming growth factor β receptor signaling SMAD2 


Conflicts of interest



  1. 1.
    Olsson AY, Cooper CS. The molecular basis of prostate cancer. Br J Hosp Med (Lond). 2005;66:612–6.CrossRefGoogle Scholar
  2. 2.
    Powell IJ, Bollig-Fischer A. Minireview: the molecular and genomic basis for prostate cancer health disparities. Mol Endocrinol. 2013;27:879–91.CrossRefPubMedGoogle Scholar
  3. 3.
    Mazaris E, Tsiotras A. Molecular pathways in prostate cancer. Nephro-urology Mon. 2013;5:792–800.CrossRefGoogle Scholar
  4. 4.
    Huang S, Liao Q, Li L, Xin D. PTTG1 inhibits SMAD3 in prostate cancer cells to promote their proliferation. Tumour Biol. 2014;35:6265–70.CrossRefPubMedGoogle Scholar
  5. 5.
    Xia Q, Li C, Bian P, Wang J, Dong S: Targeting SMAD3 for inhibiting prostate cancer metastasis. Tumour Biol 2014Google Scholar
  6. 6.
    Massague J. TGFbeta in cancer. Cell. 2008;134:215–30.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685–700.CrossRefPubMedGoogle Scholar
  8. 8.
    Kretzschmar M, Massague J. SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev. 1998;8:103–11.CrossRefPubMedGoogle Scholar
  9. 9.
    Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev. 2000;14:627–44.PubMedGoogle Scholar
  10. 10.
    Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol. 2012;13:616–30.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Xiao X, Wiersch J, El-Gohary Y, Guo P, Prasadan K, Paredes J, et al. TGFbeta receptor signaling is essential for inflammation-induced but not beta-cell workload-induced beta-cell proliferation. Diabetes. 2013;62:1217–26.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Xiao X, Gaffar I, Guo P, Wiersch J, Fischbach S, Peirish L, et al. M2 macrophages promote beta-cell proliferation by up-regulation of SMAD7. Proc Natl Acad Sci U S A. 2014;111:E1211–20.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kikuchi Y, Sasa H, Kita T, Hirata J, Tode T, Nagata I. Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivo. Anticancer Drugs. 1991;2:63–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Tode T, Kikuchi Y, Hirata J, Kita T, Imaizumi E, Nagata I. [Inhibitory effects of oral administration of ginsenoside Rh2 on tumor growth in nude mice bearing serous cyst adenocarcinoma of the human ovary]. Nihon Sanka Fujinka Gakkai zasshi. 1993;45:1275–82.PubMedGoogle Scholar
  15. 15.
    Tode T, Kikuchi Y, Kita T, Hirata J, Imaizumi E, Nagata I. Inhibitory effects by oral administration of ginsenoside Rh2 on the growth of human ovarian cancer cells in nude mice. J Cancer Res Clin Oncol. 1993;120:24–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Nakata H, Kikuchi Y, Tode T, Hirata J, Kita T, Ishii K, et al. Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jpn J Cancer Res. 1998;89:733–40.CrossRefPubMedGoogle Scholar
  17. 17.
    Tang XP, Tang GD, Fang CY, Liang ZH, Zhang LY. Effects of ginsenoside Rh2 on growth and migration of pancreatic cancer cells. World J Gastroenterol. 2013;19:1582–92.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Liu J, Shimizu K, Yu H, Zhang C, Jin F, Kondo R. Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells. Fitoterapia. 2010;81:902–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Li B, Zhao J, Wang CZ, Searle J, He TC, Yuan CS, et al. Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett. 2011;301:185–92.CrossRefPubMedGoogle Scholar
  20. 20.
    Oh M, Choi YH, Choi S, Chung H, Kim K, Kim SI, et al. Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast cancer cells. Int J Oncol. 1999;14:869–75.PubMedGoogle Scholar
  21. 21.
    Choi S, Kim TW, Singh SV. Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases. Pharm Res. 2009;26:2280–8.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Li S, Gao Y, Ma W, Guo W, Zhou G, Cheng T, et al. EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2. Tumour Biol. 2014;35:5593–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Ye H, Wu Q, Zhu Y, Guo C, Zheng X. Ginsenoside Rh2 alleviates dextran sulfate sodium-induced colitis via augmenting TGFbeta signaling. Mol Biol Rep. 2014;41:5485–90.CrossRefPubMedGoogle Scholar
  24. 24.
    Huang SQ, Liao QJ, Wang XW, Xin DQ, Chen SX, Wu QJ, et al. Rnai-mediated knockdown of pituitary tumor- transforming gene-1 (PTTG1) suppresses the proliferation and invasive potential of pc3 human prostate cancer cells. Braz J Med Biol Res. 2012;45:995–1001.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Qingchuan Zhang
    • 1
  • Bin Hong
    • 1
  • Songhua Wu
    • 1
  • Tianli Niu
    • 1
  1. 1.Department of Urology, Putuo Hospital,Shanghai University of Traditional Chinese MedicineShanghaiChina

Personalised recommendations